CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 29, 2019--
Sesen Bio (Nasdaq:SESN), a late-stage clinical company developing
targeted fusion protein therapeutics for the treatment of patients with
cancer, today announced that Company management will host a conference
call and webcast on Monday, May 13, 2019 at 8:00 a.m. EDT to review
operating results for the first quarter ended March 31, 2019 and
updated, preliminary primary and new secondary endpoint data from the
Phase 3 VISTA trial of Vicinium® for patients with high-risk
non-muscle invasive bladder cancer who have been previously treated with
To participate in the conference call, please dial (844) 831-3025
(domestic) or (315) 625-6887 (international) and refer to conference ID
7176228. The webcast can be accessed in the Investor Relations section
of the Company's website at www.sesenbio.com.
The replay of the webcast will be available in the investor section of
the Company’s website at www.sesenbio.com
for 60 days following the call.
About Sesen Bio
Sesen Bio, Inc. is a late-stage clinical
company advancing targeted fusion protein therapeutics for the treatment
of patients with cancer. The company’s lead program, Vicinium®,
also known as VB4-845, is currently in a Phase 3 registration trial, the
VISTA trial, for the treatment of high-risk, BCG un-responsive
non-muscle invasive bladder cancer (NMIBC). Vicinium is a
locally-administered targeted fusion protein composed of an anti-EPCAM
antibody fragment tethered to a truncated form of Pseudomonas
Exotoxin A for the treatment of high-risk NMIBC. For more
information, please visit the company’s website at www.sesenbio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190429005162/en/
Source: Sesen Bio, Inc.
Erin Clark, Executive Director, Strategic Planning & Investor Relations